Variable Interest Entities	3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	Variable Interest Entities As of March 31, 2026, the variable interest entities (“VIEs”) are the Affiliated Medical Groups, which are located in the United States. The Company determined that it is the primary beneficiary of these entities for accounting purposes because it has the ability to direct the activities that most significantly affect the entities’ economic performance and has the obligation to absorb the losses. Under the VIE model, the Company presents the results of operations, cash flows, and the financial position of the VIEs as part of the consolidated financial statements of the Company as if the consolidated group were a single economic entity. The assets of the VIEs can only be used to settle the obligations of the VIEs. There is no noncontrolling interest upon consolidation of the entities. The results of operations and cash flows of the VIEs are also included in the Company’s unaudited condensed consolidated financial statements. Apostrophe Pharmacy LLC and XeCare, LLC were VIEs through April 2025 and November 2025, respectively, when, as a result of changes of ownership, they became wholly-owned subsidiaries of the Company and were no longer considered VIEs. Previously, the Company was the primary beneficiary of the entities and consolidated their operations under the VIE model. The change of ownership did not have a material impact on the Company’s unaudited condensed consolidated financial statements because they were previously fully consolidated under the VIE model and had no noncontrolling interest. As of March 31, 2026 and December 31, 2025, the Company’s unaudited condensed consolidated balance sheets included current assets of $9.0 million and $6.9 million, respectively, and total assets of $9.1 million and $6.9 million, respectively, for the VIEs. As of March 31, 2026 and December 31, 2025, current and total liabilities were $6.4 million and $6.0 million, respectively. All amounts are after elimination of intercompany transactions, balances, and non-cash impact of operating leases. For the three months ended March 31, 2026 and 2025, the VIEs charged $28.4 million and $127.4 million, respectively, for services rendered. For the three months ended March 31, 2026 and 2025, operations of the VIEs generated net income of $1.6 million and a net loss of $7.7 million, respectively, inclusive of administrative expenses.

As of March 31, 2026, the variable interest entities (“VIEs”) are the Affiliated Medical Groups, which are located in the United States. The Company determined that it is the primary beneficiary of these entities for accounting purposes because it has the ability to direct the activities that most significantly affect the entities’ economic performance and has the obligation to absorb the losses. Under the VIE model, the Company presents the results of operations, cash flows, and the financial position of the VIEs as part of the consolidated financial statements of the Company as if the consolidated group were a single economic entity. The assets of the VIEs can only be used to settle the obligations of the VIEs. There is no noncontrolling interest upon consolidation of the entities. The results of operations and cash flows of the VIEs are also included in the Company’s unaudited condensed consolidated financial statements.

Apostrophe Pharmacy LLC and XeCare, LLC were VIEs through April 2025 and November 2025, respectively, when, as a result of changes of ownership, they became wholly-owned subsidiaries of the Company and were no longer considered VIEs. Previously, the Company was the primary beneficiary of the entities and consolidated their operations under the VIE model. The change of ownership did not have a material impact on the Company’s unaudited condensed consolidated financial statements because they were previously fully consolidated under the VIE model and had no noncontrolling interest.

As of March 31, 2026 and December 31, 2025, the Company’s unaudited condensed consolidated balance sheets included current assets of $9.0 million and $6.9 million, respectively, and total assets of $9.1 million and $6.9 million, respectively, for the VIEs. As of March 31, 2026 and December 31, 2025, current and total liabilities were $6.4 million and $6.0 million, respectively. All amounts are after elimination of intercompany transactions, balances, and non-cash impact of operating leases.

For the three months ended March 31, 2026 and 2025, the VIEs charged $28.4 million and $127.4 million, respectively, for services rendered. For the three months ended March 31, 2026 and 2025, operations of the VIEs generated net income of $1.6 million and a net loss of $7.7 million, respectively, inclusive of administrative expenses.